全文获取类型
收费全文 | 15818篇 |
免费 | 1122篇 |
国内免费 | 22篇 |
专业分类
耳鼻咽喉 | 200篇 |
儿科学 | 491篇 |
妇产科学 | 326篇 |
基础医学 | 2218篇 |
口腔科学 | 199篇 |
临床医学 | 2007篇 |
内科学 | 3254篇 |
皮肤病学 | 258篇 |
神经病学 | 1688篇 |
特种医学 | 415篇 |
外国民族医学 | 2篇 |
外科学 | 1664篇 |
综合类 | 159篇 |
一般理论 | 12篇 |
预防医学 | 1762篇 |
眼科学 | 369篇 |
药学 | 1012篇 |
中国医学 | 28篇 |
肿瘤学 | 898篇 |
出版年
2023年 | 101篇 |
2022年 | 166篇 |
2021年 | 415篇 |
2020年 | 213篇 |
2019年 | 360篇 |
2018年 | 379篇 |
2017年 | 317篇 |
2016年 | 333篇 |
2015年 | 360篇 |
2014年 | 554篇 |
2013年 | 752篇 |
2012年 | 1201篇 |
2011年 | 1227篇 |
2010年 | 607篇 |
2009年 | 595篇 |
2008年 | 1028篇 |
2007年 | 1036篇 |
2006年 | 1020篇 |
2005年 | 1004篇 |
2004年 | 996篇 |
2003年 | 907篇 |
2002年 | 816篇 |
2001年 | 153篇 |
2000年 | 127篇 |
1999年 | 172篇 |
1998年 | 173篇 |
1997年 | 130篇 |
1996年 | 135篇 |
1995年 | 118篇 |
1994年 | 94篇 |
1993年 | 89篇 |
1992年 | 86篇 |
1991年 | 103篇 |
1990年 | 85篇 |
1989年 | 74篇 |
1988年 | 75篇 |
1987年 | 89篇 |
1986年 | 88篇 |
1985年 | 80篇 |
1984年 | 70篇 |
1983年 | 50篇 |
1982年 | 47篇 |
1981年 | 53篇 |
1980年 | 50篇 |
1979年 | 42篇 |
1978年 | 32篇 |
1977年 | 35篇 |
1976年 | 34篇 |
1975年 | 40篇 |
1974年 | 31篇 |
排序方式: 共有10000条查询结果,搜索用时 0 毫秒
1.
2.
Thomas Asendorf Robin Henderson Heinz Schmidli Tim Friede 《Statistics in medicine》2019,38(9):1503-1528
In some diseases, such as multiple sclerosis, lesion counts obtained from magnetic resonance imaging (MRI) are used as markers of disease progression. This leads to longitudinal, and typically overdispersed, count data outcomes in clinical trials. Models for such data invariably include a number of nuisance parameters, which can be difficult to specify at the planning stage, leading to considerable uncertainty in sample size specification. Consequently, blinded sample size re-estimation procedures are used, allowing for an adjustment of the sample size within an ongoing trial by estimating relevant nuisance parameters at an interim point, without compromising trial integrity. To date, the methods available for re-estimation have required an assumption that the mean count is time-constant within patients. We propose a new modeling approach that maintains the advantages of established procedures but allows for general underlying and treatment-specific time trends in the mean response. A simulation study is conducted to assess the effectiveness of blinded sample size re-estimation methods over fixed designs. Sample sizes attained through blinded sample size re-estimation procedures are shown to maintain the desired study power without inflating the Type I error rate and the procedure is demonstrated on MRI data from a recent study in multiple sclerosis. 相似文献
3.
4.
5.
Robin L. Bissinger MSN RNC NNP Cheryl A. Carlson MS RNC NNP 《Newborn and Infant Nursing Reviews》2006,6(2):87
Surfactant, a complex substance containing specific proteins and phospholipids, is essential for gas exchange in the lungs. Research shows that surfactant not only lowers surface tension, but also plays a role in host defense. Surfactant replacement therapy is a cornerstone in the treatment of respiratory distress syndrome in premature infants. New information on endogenous surfactant composition including surfactant apoproteins has led to advances in the surfactant replacement products currently available. Because of the success of surfactant deficiency treatment in neonates, surfactant replacement therapy has been studied in both the pediatric and adult population for the treatment of other respiratory disorders. This article describes the composition, metabolism, and function of endogenous surfactant and other uses of surfactant replacement therapies in neonates. 相似文献
6.
Tauseef Ahmed Alan Yagoda Howard I. Scher Cora Sternberg Robin C. Watson 《Investigational new drugs》1986,4(2):171-174
Summary Deaza-aminopterin is a folate analog which is transported more rapidly than methotrexate into cells and appears to be more active than methotrexate against human and animal tumor in vitro. Fifteen patients with advanced urothelial tract cancer were given deaza-aminopterin 30–37.5 mg/m2 IV QW. In responding patients drug was given QOW after 4–6 consecutive doses. Doses were escalated or de-escalated by 7.5 mg/m2 depending on toxicity. Twelve patients had received prior chemotherapy which included methotrexate in nine. Three patients achieved a partial remission lasting 1, 3, and 3 months respectively: all responders had previously failed methotrexate after an initial response to a methotrexate containing regimen. None of the six patients who were methotrexate naive responded to deaza-aminopterin; 3 subsequently received methotrexate without response. Mild mucositis was universal and in 5 was severe. Six patients had an increase in liver transaminases probably secondary to anti-folate hepatotoxicity. Other toxicities included diarrhea, nausea, skin rash and fever. Further studies are needed to define the precise efficacy of deaza-aminopterin in patients with urothelial tract cancers. 相似文献
7.
8.
Patients with Fabry disease on dialysis in the United States. 总被引:9,自引:0,他引:9
Ravi Thadhani Myles Wolf Michael L West Marcello Tonelli Robin Ruthazer Gregory M Pastores Gregorio T Obrador 《Kidney international》2002,61(1):249-255
BACKGROUND.: Fabry disease results from an X-linked deficiency of lysosomal alpha-galactosidase A and is a rare cause of end-stage renal disease. Little is known about the characteristics of patients with Fabry disease that initiate dialysis in the United States, although data from Europe suggests these individuals have a poor survival. METHODS.: Using the United States Renal Disease System database, we first studied in detail 42 Fabry patients who initiated dialysis between April 1995 (following the introduction of the new detailed HCFA 2728 form) and July 1998. To examine crude survival in a larger cohort, 95 Fabry patients were studied who initiated dialysis between 1985 and 1993, similar to the European Registry. Diabetic and non-diabetic controls matched by age, gender, race, year of dialysis initiation, and initial dialysis modality were examined for comparison. RESULTS.: During the years 1995 to 1998, the mean age of Fabry patients that initiated dialysis was 42 years, 83% were Caucasian, and 10% were African American. Despite the X-linked inheritance of Fabry disease, 12% of Fabry patients on dialysis were female. At initiation of dialysis mean serum albumin and creatinine were significantly higher and mean body mass index was significantly lower among Fabry patients, but mean glomerular filtration rate was similar to controls. Fabry patients tended to have a lower three-year survival compared to non-diabetic controls, but the results were not significantly different. In a larger cohort of Fabry patients who initiated dialysis between 1985 and 1993, the three-year survival of Fabry patients was significantly lower than non-diabetic controls: 63% (95% CI, 50 to 75%) versus 74% (95% CI, 67 to 80%; P=0.03). CONCLUSION.: End-stage renal disease is associated with significant morbidity and mortality among patients with Fabry disease. Recent evidence that progression of Fabry disease may be attenuated by enzyme replacement therapy necessitates increased awareness of Fabry disease and its comorbidities. 相似文献
9.
10.